X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA DIVIS LABORATORIES AJANTA PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 20.6 18.4 112.1% View Chart
P/BV x 8.9 4.0 223.9% View Chart
Dividend Yield % 0.7 1.6 43.3%  

Financials

 AJANTA PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
DIVIS LABORATORIES
Mar-16
AJANTA PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,7202,484 69.3%   
Low Rs1,103918 120.1%   
Sales per share (Unadj.) Rs194.6142.3 136.8%  
Earnings per share (Unadj.) Rs45.241.9 108.0%  
Cash flow per share (Unadj.) Rs50.346.3 108.5%  
Dividends per share (Unadj.) Rs8.0010.00 80.0%  
Dividend yield (eoy) %0.60.6 96.4%  
Book value per share (Unadj.) Rs132.0161.5 81.7%  
Shares outstanding (eoy) m88.77265.47 33.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.312.0 60.7%   
Avg P/E ratio x31.240.6 76.9%  
P/CF ratio (eoy) x28.136.7 76.5%  
Price / Book Value ratio x10.710.5 101.5%  
Dividend payout %17.723.9 74.1%   
Avg Mkt Cap Rs m125,299451,525 27.8%   
No. of employees `000NA3.7 0.0%   
Total wages/salary Rs m2,5703,649 70.4%   
Avg. sales/employee Rs ThNM10,184.4-  
Avg. wages/employee Rs ThNM984.1-  
Avg. net profit/employee Rs ThNM2,998.5-  
INCOME DATA
Net Sales Rs m17,27537,764 45.7%  
Other income Rs m166848 19.6%   
Total revenues Rs m17,44238,612 45.2%   
Gross profit Rs m5,80714,138 41.1%  
Depreciation Rs m4511,182 38.1%   
Interest Rs m4923 210.8%   
Profit before tax Rs m5,47413,781 39.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4602,662 54.8%   
Profit after tax Rs m4,01411,119 36.1%  
Gross profit margin %33.637.4 89.8%  
Effective tax rate %26.719.3 138.0%   
Net profit margin %23.229.4 78.9%  
BALANCE SHEET DATA
Current assets Rs m7,63930,947 24.7%   
Current liabilities Rs m2,7155,195 52.3%   
Net working cap to sales %28.568.2 41.8%  
Current ratio x2.86.0 47.2%  
Inventory Days Days43117 37.0%  
Debtors Days Days7985 92.4%  
Net fixed assets Rs m6,91417,027 40.6%   
Share capital Rs m177531 33.3%   
"Free" reserves Rs m11,44242,341 27.0%   
Net worth Rs m11,72142,877 27.3%   
Long term debt Rs m1495 3,163.8%   
Total assets Rs m14,81449,684 29.8%  
Interest coverage x112.9595.0 19.0%   
Debt to equity ratio x00 11,574.1%  
Sales to assets ratio x1.20.8 153.4%   
Return on assets %27.422.4 122.3%  
Return on equity %34.225.9 132.1%  
Return on capital %46.532.2 144.5%  
Exports to sales %55.185.3 64.7%   
Imports to sales %6.022.9 26.2%   
Exports (fob) Rs m9,52732,198 29.6%   
Imports (cif) Rs m1,0388,654 12.0%   
Fx inflow Rs m10,42232,270 32.3%   
Fx outflow Rs m1,6788,775 19.1%   
Net fx Rs m8,74423,496 37.2%   
CASH FLOW
From Operations Rs m3,26410,379 31.4%  
From Investments Rs m-2,093-4,135 50.6%  
From Financial Activity Rs m-1,186-6,241 19.0%  
Net Cashflow Rs m-153 -448.5%  

Share Holding

Indian Promoters % 73.8 52.0 141.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 11.8 13.1%  
FIIs % 7.6 19.0 40.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 17.2 98.8%  
Shareholders   20,968 31,796 65.9%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   GSK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  JUBILANT LIFE SCIENCES  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Share Buybacks, GST Cess on Motor Vehicles, and Top Stocks in Focus Today(Pre-Open)

Indian share markets witnessed buying interest on Wednesday and finished their session in the green for the second straight session. Heavy buying was seen in realty stocks, metal stocks and bank stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Aug 24, 2017 09:23 AM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS